STAFF INVESTIGATORS
调查人员
基本信息
- 批准号:7529350
- 负责人:
- 金额:$ 6.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-07-06 至 2012-03-31
- 项目状态:已结题
- 来源:
- 关键词:American Society of Clinical OncologyAngiogenesis InhibitorsAntineoplastic AgentsArchivesAreaAwardB-LymphocytesBiological MarkersBiopsyBreastCellsChairpersonCisplatinClinicClinicalClinical InvestigatorClinical ResearchClinical TrialsClinical Trials DesignCombination ChemotherapyCorrelative StudyDataDevelopmentDevelopmental Therapeutics ProgramDiagnosisDiffuseDiseaseDisease-Free SurvivalDrug KineticsEastern Cooperative Oncology GroupEnd PointEpidermal Growth Factor ReceptorEtoposideExtensive StageFCGR3B geneFollicular LymphomaFundingGenesGenetic PolymorphismGuidelinesHematologic NeoplasmsHematologyHodgkin DiseaseImmune responseImmunohistochemistryInternationalJointsK-Series Research Career ProgramsLaboratoriesLeadershipLimited StageLungLymphomaMS4A1 geneMalignant NeoplasmsMalignant neoplasm of lungMedicineMedlone 21Mentored Clinical Oncology AwardMentored Clinical Scientist AwardMentored Patient-Oriented Research Career Development AwardMethodsMolecularMolecular ProfilingMonoclonal AntibodiesMonoclonal Antibody TherapyMultidrug Resistance GeneNon-Hodgkin&aposs LymphomaOperative Surgical ProceduresOralOutcomeParticipantPathway interactionsPatientsPeripheralPharmaceutical PreparationsPharmacology Shared ResourcePhasePhase I Clinical TrialsPhase I/II TrialPhase II Clinical TrialsPopulationPredictive FactorPredictive ValuePrincipal InvestigatorPrior TherapyPrognostic FactorProtein Tyrosine KinaseRadiationRadioimmunotherapyRefractoryRelapseResearchResearch ActivityResearch DesignResearch PersonnelResearch Project GrantsRetrospective StudiesRoleSTAT3 geneScienceSouthwest Oncology GroupStagingStem cell transplantStem cellsT-Cell LymphomaT-LymphocyteTestingTherapeuticTimeTissue MicroarrayTissuesTranslatingTranslational ResearchTranslational Research Shared ResourceVascular Endothelial Growth FactorsWorkauthoritybasebevacizumabcancer pharmacologychemotherapyclinical effectconceptdesigndrug developmentgemcitabineimprovedinhibitor/antagonistlapatiniblung small cell carcinomalymph nodesmacrophagemembermodel developmentnovelnovel therapeuticsoncologyprofessorprogramsprotocol developmentquality assuranceresponserituximabtositumomabtranslational studytumorigenesis
项目摘要
Two staff investigators are proposed, both to serve in the function as Deputy Associate Directors for Clinical
Research. Dr. Afshin Dowlati, an expert in novel therapeutic development in lung cancer, and Dr. John
Sweetenham, an expert in lymphoma therapeutics, are both accomplished clinical investigators with
considerable leadership capacity to coordinate clinical trials research emphasizing investigator-initiated
efforts. As staff investigators, they will have focused time to devote to clinical trials development and
oversight with special emphasis on investigator-initiated trials that cut across scientific programs and involve
the Case CCC clinical trials disease teams. As staff investigators, they will have the prominence and
authority to assist investigators in protocol development and design, and in efficient, safe management with
a high degree of quality assurance during early phase drug development.
提出了两名员工调查人员
研究。 Afshin Dowlati博士是肺癌新型治疗发展专家和John博士
Sweetenham是淋巴瘤治疗剂的专家,都是经验丰富的临床研究者
协调临床试验研究的相当大的领导能力,强调研究者发起的研究
努力。作为员工调查人员,他们将集中精力用于临床试验开发和
监督,特别强调研究者发起的试验,这些试验跨越了科学计划并涉及
病例CCC临床试验疾病小组。作为员工调查人员,他们将具有突出性和
授权协助调查人员进行协议开发和设计,并与
早期药物开发期间,高质量保证。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
AFSHIN DOWLATI其他文献
AFSHIN DOWLATI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('AFSHIN DOWLATI', 18)}}的其他基金
REBECCAMYCIN IN UNRESECTABLE OR METASTATIC HEPATOBILIARY CANCERS
瑞贝卡霉素治疗不可切除或转移性肝胆癌
- 批准号:
7202755 - 财政年份:2005
- 资助金额:
$ 6.35万 - 项目类别:
Rebeccamycin in unresectable or metastatic hepatobiliary cancers
瑞贝卡霉素治疗不可切除或转移性肝胆癌
- 批准号:
6974961 - 财政年份:2004
- 资助金额:
$ 6.35万 - 项目类别:
相似国自然基金
血管生成抑制剂通过肿瘤相关高内皮静脉调控三阴乳腺癌三级淋巴结构成熟的机制研究
- 批准号:82373278
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
免疫检查点抑制剂联合抗血管生成治疗肝癌协同机制的定量磁共振研究
- 批准号:82001786
- 批准年份:2020
- 资助金额:24 万元
- 项目类别:青年科学基金项目
基于不对称双-β-咔啉骨架的血管生成抑制剂的设计、合成及活性研究
- 批准号:
- 批准年份:2020
- 资助金额:40 万元
- 项目类别:地区科学基金项目
抗血管生成抑制乳腺癌生长转移的作用机制及其靶向抑制剂研究
- 批准号:81911530168
- 批准年份:2019
- 资助金额:40 万元
- 项目类别:国际(地区)合作与交流项目
基于肿瘤微环境多模影像评价血管生成抑制剂联合CTLA-4免疫靶向序贯治疗及其机制研究
- 批准号:81971672
- 批准年份:2019
- 资助金额:55 万元
- 项目类别:面上项目